 | Up a level |
Tettero, Jesse M; Al-Badri, Waleed K W; Ngai, Lok Lam; Bachas, Costa; Breems, Dimitri A; van Elssen, Catharina H M J; Fischer, Thomas; Gjertsen, Bjorn T; van Gorkom, Gwendolyn N Y; Gradowska, Patrycja; Greuter, Marjolein J E; Griskevicius, Laimonas; Juliusson, Gunnar; Maertens, Johan; Manz, Markus G; Pabst, Thomas; Passweg, Jakob; Porkka, Kimmo; Löwenberg, Bob; Ossenkoppele, Gert J; ... (2022). Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis. Frontiers in oncology, 12, p. 999822. Frontiers Research Foundation 10.3389/fonc.2022.999822
Löwenberg, Bob; Pabst, Thomas; Maertens, Johan; Gradowska, Patrycja; Biemond, Bart J; Spertini, Olivier; Vellenga, Edo; Griskevicius, Laimonas; Tick, Lidwine W; Jongen-Lavrencic, Mojca; van Marwijk Kooy, Marinus; Vekemans, Marie-Christiane; van der Velden, Walter J F M; Beverloo, Berna; Michaux, Lucienne; Graux, Carlos; Deeren, Dries; de Weerdt, Okke; van Esser, Joost W J; Bargetzi, Mario; ... (2021). Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood advances, 5(4), pp. 1110-1121. American Society of Hematology 10.1182/bloodadvances.2020003855
